News|Articles|July 7, 2024

7 FDA Drug Decisions Anticipated Before the End of 2024

Name: Chamil Codipilly, MD: Vonoprazan and PCABs for GERD
Uploaded: 2024-07-07T19:00:00Z
Duration: 8 min 15 s
Description: The potassium-competitive acid blocker drug class is coming to US digestive disease management. How does it fare to standard antacids and PPIs for GERD?

Author(s)Kevin Kunzmann

After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.

After a very busy first half of 2024 in the pharmaceutical pipeline, a number of high-interest and practice-implicative US Food and Drug Administration (FDA) decisions remain to close the year.